Diabetes can absolutely contribute to weight gain, and often does so through multiple channels at once. The disease itself alters how your body handles energy, and many of the medications used to treat it push the scale upward as a side effect. In the landmark UK Prospective Diabetes Study, people on intensive blood-sugar control gained an average of about 3 kg more than those on conventional treatment, with those assigned to insulin gaining the most. Understanding why this happens, and what newer options can change the equation, matters for anyone trying to manage both their blood sugar and their body weight.
How Insulin Drives Fat Storage
Insulin is the hormone that tells your cells to absorb glucose from the bloodstream. It also tells fat cells to store energy and discourages them from releasing it. In a healthy body, that system stays in balance. In diabetes, the balance is off in ways that can nudge weight upward.
In type 2 diabetes, cells become resistant to insulin’s signal, so the pancreas pumps out more of it to compensate. Higher circulating insulin levels mean more fat storage signaling. The carbohydrate-insulin model of obesity suggests that high-glycemic processed carbohydrates amplify this loop: they spike insulin, which promotes calorie deposition in fat tissue, ramps up hunger, and may lower the rate at which you burn energy at rest.1Europe PMC. The Carbohydrate-Insulin Model of Obesity: Beyond “Calories In, Calories Out” That model is debated among researchers, but the basic point that elevated insulin promotes fat accumulation is well established.
In type 1 diabetes, the problem is the mirror image. Before diagnosis and treatment, the body makes little or no insulin, so glucose stays in the blood and gets dumped into the urine. People often lose weight rapidly before they’re diagnosed. Once they start taking insulin, the body can finally use glucose again, calories that were being wasted in the urine get absorbed, and weight comes back. That initial rebound is recovering what was lost, but the weight gain can continue beyond that recovery point.
Medications That Push Weight Up
Not all diabetes drugs are equal when it comes to body weight. Several of the older, widely prescribed classes are well known to cause weight gain, and for different reasons.
- Insulin therapy: Injected insulin lowers blood sugar effectively, but it promotes fat storage just as the body’s own insulin does. It also eliminates the calorie loss through urine that happens when blood sugar runs high. The potential for insulin-related weight gain frequently leads clinicians to delay starting insulin therapy, even when blood sugar control demands it.2PubMed Central. Insulin therapy and type 2 diabetes: management of weight gain
- Sulfonylureas: These drugs work by stimulating the pancreas to release more insulin. The extra insulin lowers blood sugar, but it also promotes fat synthesis. On top of that, sulfonylureas can cause blood sugar to drop too low, which leads people to eat more to correct or prevent those lows.3Obesity Pillars. Weight-centric treatment of type 2 diabetes mellitus
- Thiazolidinediones (TZDs): Pioglitazone and rosiglitazone improve insulin sensitivity, which sounds like it should help. But they also cause the body to retain fluid, partly by increasing sodium reabsorption in the kidneys and partly by making blood vessels in fat tissue more permeable.4PubMed Central. Renal and vascular mechanisms of thiazolidinedione-induced fluid retention The result is swelling and a higher number on the scale, some of which is water rather than fat.
All three classes, along with meglitinides (a less commonly used cousin of sulfonylureas), are consistently associated with weight gain in clinical reviews.5PubMed Central. Body Weight Considerations in the Management of Type 2 Diabetes For decades, these were the main options, which meant that getting your blood sugar under control almost inevitably meant gaining weight. That trade-off shaped how patients and doctors thought about diabetes management.
The Hypoglycemia-Overeating Cycle
One of the sneakier drivers of weight gain in diabetes has nothing to do with hormones or fat cells directly. It’s behavioral: when your blood sugar drops too low, you eat to bring it back up. That sounds reasonable, and it is. The problem is that the fear and unpleasantness of low blood sugar often lead people to overcompensate.
A review of the mechanisms behind insulin-associated weight gain identified several contributing factors: blood glucose dropping below the level where the kidneys spill sugar without a matching reduction in food intake, and both conscious and unconscious increases in eating driven by fear of hypoglycemia or the experience of it.6PubMed. Insulin-associated weight gain in diabetes–causes, effects and coping strategies In other words, the treatment itself creates a situation where eating extra feels medically necessary.
Research on people with type 1 diabetes has found that fear of low blood sugar can trigger overeating even when blood sugar isn’t objectively low. If someone perceives their levels as dropping, they may break dietary restraint and reach for sugary foods they’d normally avoid. In some people, eating those “off-limits” foods can trigger a loss of control and a binge eating episode, creating a cycle where diabetes management and disordered eating patterns reinforce each other.7PubMed Central. Fear of Hypoglycemia and Disordered Eating Behavior in Type 1 Diabetes This isn’t a character flaw; it’s a predictable psychological response to living with a condition where low blood sugar can make you shaky, confused, or even unconscious.
Tighter Control Often Means More Weight
Here’s an uncomfortable reality in diabetes care: the better you control your blood sugar with older therapies, the more weight you tend to gain. This was demonstrated clearly in two of the most important diabetes trials ever conducted.
In the Diabetes Control and Complications Trial (DCCT), which studied people with type 1 diabetes, those on intensive insulin therapy gained about 5 kg in the first year, compared with about 2.4 kg for those on standard treatment.8PubMed. Weight gain associated with intensive therapy in the diabetes control and complications trial In the UK Prospective Diabetes Study (UKPDS), which studied type 2 diabetes, intensive treatment also produced more weight gain than conventional treatment, with those on insulin gaining the most (about 4 kg) compared with those on sulfonylureas (roughly 1.7 to 2.6 kg depending on the specific drug).9PubMed. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
Both trials proved that tighter blood sugar control reduces the long-term complications of diabetes, like nerve damage, kidney disease, and vision loss. But the weight gain that came along with it was a genuine cost, and for many patients it became a reason to resist intensifying treatment. Doctors found themselves in a bind: push for better glucose control and watch the patient gain weight, or accept looser control to avoid that outcome. This tension persisted for years until newer drug classes changed the calculus.
Newer Drugs That Shift the Equation
The development of two drug classes has transformed the weight conversation in type 2 diabetes. SGLT2 inhibitors (drugs like empagliflozin and dapagliflozin) work by blocking glucose reabsorption in the kidneys, so excess sugar gets excreted in urine. GLP-1 receptor agonists (such as semaglutide and liraglutide) mimic a gut hormone that slows stomach emptying and reduces appetite. Both classes lower blood sugar while also promoting weight loss, typically around 2 to 3 kg on average in clinical trials.10PubMed. Weight loss variability with SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes mellitus and obesity: Mechanistic possibilities
When combined, these drugs can produce even greater weight loss. A meta-analysis found that adding a GLP-1 receptor agonist to an SGLT2 inhibitor led to about 1.6 kg more weight loss than the SGLT2 inhibitor alone.11Scientific Reports. Efficacy and safety of GLP-1 receptor agonists as add on to SGLT2 inhibitors in type 2 diabetes mellitus: A meta analysis The weight loss with these drugs varies widely between individuals, but the direction is consistently downward rather than upward.
This shift matters enormously. For the first time, people with type 2 diabetes have options that address both blood sugar and weight simultaneously. The rise of GLP-1 drugs for weight loss in people without diabetes (under brand names like Ozempic and Wegovy) has drawn massive public attention, but their original purpose was diabetes management, and the weight benefit was a welcome feature, not the sole goal.
Water Weight Versus Fat
Not all weight gain in diabetes is fat. Insulin has a well-documented effect on the kidneys: it promotes sodium retention, which pulls water along with it. When someone with poorly controlled diabetes starts or intensifies insulin therapy, the rapid improvement in blood sugar can trigger noticeable fluid retention.12PubMed Central. Insulin-Induced Edema in a Patient with Type 2 Diabetes Mellitus In rare cases, this can progress to visible swelling in the legs and feet, a condition sometimes called insulin edema.13PubMed Central. Insulin oedema in newly diagnosed type 1 diabetes mellitus
The distinction between fluid and fat is worth knowing because it changes both the timeline and the response. Fluid-related weight gain tends to show up quickly after starting or adjusting insulin, and it often resolves on its own within weeks as the body adapts. Fat accumulation is slower and more persistent. If you see a sudden jump on the scale right after starting insulin, fluid retention is a likely contributor. A gradual upward trend over months is more likely to reflect actual changes in body composition.
Thiazolidinediones, as mentioned earlier, cause weight gain through both mechanisms: they increase fluid retention and promote fat cell maturation. That double hit is one reason they’ve fallen out of favor compared with newer options.
Weight Regain After a Type 1 Diagnosis
Children and adolescents newly diagnosed with type 1 diabetes often arrive underweight. A study tracking weight after diagnosis found that average body mass was below normal at the time of diagnosis, then rose quickly in the first three months of insulin treatment.14PubMed. Changes in weight and BMI following the diagnosis of type 1 diabetes in children and adolescents This initial rebound makes sense: the body is recovering from a period where it couldn’t use calories properly. But the trajectory didn’t always level off. In females, weight continued to creep upward between three and six years after diagnosis.
For parents and young patients, this pattern can be confusing. The first few months of insulin therapy feel like a healthy recovery. The question becomes when recovery ends and excess gain begins, and there’s no clean dividing line. Healthcare providers typically monitor growth trajectories closely during these years, but the experience of watching the scale climb after a scary diagnosis can be emotionally loaded even when the numbers are medically appropriate.
When the Fear of Gaining Weight Becomes Dangerous
The link between diabetes and weight gain creates a uniquely risky situation for eating disorders. In type 1 diabetes, some people discover that skipping or reducing their insulin doses causes blood sugar to spike and glucose to spill into the urine, taking calories with it. This leads to weight loss, but at the cost of dangerously high blood sugar that damages organs over time. The behavior has been called “diabulimia,” and it has been described as one of the most dangerous eating disorders because of the severe medical consequences of prolonged high blood sugar.15PubMed Central. Intentional Insulin Omission (Diabulimia) in Patients with Insulin-Dependent Diabetes: An Eating Disorder? A Systematic Review
The motivations behind insulin omission are complex. Fear that better blood sugar control will cause weight gain is a core driver, but there are also elements of rejecting the diabetic identity, wanting to feel “normal,” and sometimes using hyperglycemia as a form of emotional numbing.15PubMed Central. Intentional Insulin Omission (Diabulimia) in Patients with Insulin-Dependent Diabetes: An Eating Disorder? A Systematic Review Deliberate insulin restriction is unique to people with insulin-dependent diabetes and represents a disordered eating behavior that doesn’t map neatly onto traditional categories like anorexia or bulimia.16PubMed. Insulin restriction or omission in Type 1 Diabetes Mellitus: a meta-synthesis of individuals’ experiences of diabulimia
This is one of the clearest examples of how the relationship between diabetes and weight gain can become psychologically harmful. When the medical advice to take your insulin comes with a known side effect of weight gain, and the culture around you prizes thinness, the temptation to withhold insulin is understandable even as it’s medically catastrophic. If you or someone you know with type 1 diabetes is struggling with this, it warrants a conversation with a care team experienced in both diabetes and eating disorders.
Sleep, Stress, and the Gut
Diabetes doesn’t exist in isolation. Several adjacent biological systems are disrupted in people with diabetes, and those disruptions can independently promote weight gain.
Sleep problems are common in diabetes, and they create their own metabolic trouble. Poor sleep and circadian disruption are associated with metabolic changes that may contribute to weight gain by altering when and how much you eat, disrupting energy balance, impairing glucose tolerance, and promoting inflammation.17PubMed Central. Metabolic consequences of sleep and circadian disorders People with diabetes are more likely than average to have sleep apnea, restless legs, and insomnia, meaning they’re disproportionately exposed to these effects.
Chronic stress adds another layer. The body’s stress-response system, centered on cortisol, is often dysregulated in type 2 diabetes. A flattened daily cortisol pattern, where levels don’t rise and fall normally throughout the day, has been linked to insulin resistance. Managing a chronic illness is itself a source of ongoing stress, which can feed back into metabolic disruption and weight gain through increased cortisol signaling and stress-driven eating.
The gut microbiome is an active area of research as well. Animal studies and human observational data suggest that altered bacterial populations in the gut may contribute to obesity and insulin resistance by extracting more energy from food, increasing gut permeability, and triggering low-grade inflammation.18PubMed Central. Obesity, diabetes, and gut microbiota: the hygiene hypothesis expanded? People with type 2 diabetes tend to have different gut microbial profiles compared with people without the disease, and those differences are associated with increased energy extraction from carbohydrates and higher levels of inflammatory molecules.19The Journal of Clinical Endocrinology & Metabolism. Exploring the Gut Microbiota: Key Insights Into Its Role in Obesity, Metabolic Syndrome, and Type 2 Diabetes Whether these gut changes are a cause or consequence of weight gain and diabetes remains an open question, but they likely amplify the problem once it’s underway.
Appetite Hormones and the Hunger Signal
Two hormones that regulate hunger, leptin and ghrelin, behave differently in people with type 2 diabetes. Leptin is produced by fat cells and is supposed to signal fullness to the brain. Ghrelin, produced in the stomach, signals hunger. In type 2 diabetes, insulin resistance appears to interfere with how these signals are processed. Many people with type 2 diabetes have high levels of leptin but are resistant to its effects, a situation similar to how their cells are resistant to insulin. The result is that the brain doesn’t get the “you’re full” signal as clearly as it should.20PubMed Central. Leptin and ghrelin dynamics: unraveling their influence on food intake, energy balance, and the pathophysiology of type 2 diabetes mellitus
This matters because it means the difficulty of maintaining a healthy weight with diabetes isn’t just about willpower or medication side effects. The hunger and satiety signals themselves may be unreliable. When your body is telling you to eat even though you’ve had enough calories, maintaining weight becomes a fight against your own physiology. GLP-1 receptor agonists partly address this by acting on the brain’s appetite centers, which is one reason they’ve been so effective for both blood sugar and weight. But for people not on these newer drugs, the mismatch between actual caloric need and perceived hunger is a real, biologically grounded obstacle.
Practical Steps That Help
If you have diabetes and are gaining weight, the single most impactful conversation to have is with your prescriber about which medications you’re on. Switching from a sulfonylurea to a drug class that’s weight-neutral or promotes weight loss can make a meaningful difference without sacrificing blood sugar control. Not everyone is a candidate for every drug, and cost and insurance coverage play a role, but the treatment landscape has changed enough that the old inevitability of diabetes-related weight gain is no longer a given.
Beyond medication, a few principles help. Treating hypoglycemia with a measured amount of fast-acting carbohydrate, rather than raiding the pantry in a panic, reduces the caloric overshoot that comes with lows. Monitoring helps you learn the difference between actual low blood sugar and the anxiety that one might be coming. Strength training improves insulin sensitivity in muscle tissue, which can reduce the total amount of insulin your body needs (or the dose you inject), indirectly reducing insulin’s weight-promoting effects. And addressing sleep quality, stress, and mental health isn’t a soft add-on; these factors have direct metabolic consequences that compounds with everything else happening in a diabetic body.